Archives
- Sunil Shah, CEO of o2h ventures, wins the Cambridge Independent Science and Technology Awards as CEO of the Year 16 April, 2021
- University of Sussex and o2h Ventures Announce Creation and Investment in Stingray Bio, a Company for New Oncology Drugs Targeting the LMTK3 Kinase Pathway 8 April, 2021
- The o2h human health S/EIS flagship fund – Fully Deployed 1 April, 2021
- o2h Ventures invests into SomaServe’s successful Series A funding round 31 March, 2021
- o2h Ventures invests in PhoreMost Series B financing 23 March, 2021
- o2h Human Health EIS Fund leads an investment into Kuano, using quantum and AI to accelerate the development of new medicine. 25 February, 2021
- o2h ventures backed Small Pharma receives approval for world’s first DMT for depression clinical trial 22 February, 2021
- o2h Ventures invests into the UCL spin out company SomaServe. 22 February, 2021
- o2h ventures – making waves in knowledge intensive and SEIS investing 21 December, 2020
invest in the growth potential of UK life science & AI